DBV Technologies to Present Preclinical Data on its Viaskin(R) Technology for RSV Vaccination at the 2015 RSV Vaccines for the World Meeting

BAGNEUX, France, Nov. 18, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today presented new preclinical data on the use of its Epicutaneous Immunotherapy (EPIT®), Viaskin® patch technology for vaccination against respiratory syncytial virus (RSV) at the RSV Vaccines for the World 2015 (RSVVW) meeting in La Jolla, California, November 18-20, 2015.

Abstract titled, "Preclinical evaluation of a novel Epicutaneous vaccine against respiratory syncytial virus," will be presented during the poster session at the RSVVW meeting. In the preclinical study, we observed an immunogenic response in mice and swine treated with Viaskin® with a patented formulation containing an N-FsII antigen (Viaskin®-N-FsII), developed by the French National Institute for Agronomical Research, or INRA, and that Viaskin®-N-FsII promoted a Th1/Th17 oriented immune response. Due to Viaskin's novel delivery mechanism, which does not require any injection or skin preparation before application, the Viaskin®-N-FsII epicutaneous vaccine could potentially provide a safe solution for vaccination against RSV in newborns. However, further preclinical and clinical studies will need to support the safety and efficacy of this treatment.

Dr. Lucie Mondoulet, Deputy Chief Scientific Officer of DBV Technologies said: "We are very proud of the scientific insights we have gained from these preclinical results and our collaboration with the INRA. These data demonstrate the potential efficacy of the Viaskin® technology and the N-FsII antigen in a protective RSV vaccine without requiring the use of needles. The growing incidence of bronchiolitis cases in infants and the economic burden of this disease emphasize the need for a safe and efficient way to enhance the protection against RSV infection".

In collaboration the INRA's Molecular Virology and Immunology Unit (VIM), DBV's Viaskin®-N-FsII preclinical program will aim to deliver in vivo proof of concept data supporting the use of Viaskin for the preventive vaccination of RSV in pediatric population.

Dr. Sabine Riffault, Director of VIM department at INRA said: "The scientific collaboration with DBV Technologies has given us a unique opportunity to investigate a potential safe, non-invasive delivery route for our new antigenic platform against RSV. The combination of our respective technologies has proven promising in the competitive and challenging field of infant vaccination against bronchiolitis."

About INRA and DBV Technologies Collaboration RSV

Human respiratory syncytial virus (hRSV) is the leading cause of severe respiratory diseases and hospitalization in infants during the first six months of life. The RSV pathogen, which was discovered in 1956, continues to cause a large number of hospitalizations due to associated respiratory diseases, and it is considered a health and economic burden worldwide, especially in developing countries. With the French Institute for Agricultural Research, or INRA, DBV is developing a new vaccine strategy for RSV in infants. This project aims to provide preclinical proof of concept for an innovative, safe and effective pediatric vaccine against RSV. This project is funded by the French National Research Agency, or ANR.

About DBV Technologies

DBV Technologies created the Viaskin® patch, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin while avoiding compound transfer to the blood. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergy patients, for which there are currently no approved treatments. DBV's food allergy programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis and exploring potential applications of its platform in vaccines and for the treatment selected immune diseases with unmet medical needs.

DBV Technologies has global headquarters in Paris, France and New York, NY, USA. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Forward Looking Statements

This press release contains forward-looking statements, including statements about the potential safety and efficacy of Epicutaneous Immunotherapy (EPIT®) via Viaskin® and the Company's preclinical and clinical development plans. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. The Company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2014 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.

DBV Technologies Contacts
Nathalie Donne
Director, Corporate Communication & Business Development
Tél. : +33(0)1 55 42 78 72
nathalie.donne@dbv-technologies.com
Susanna Mesa
VP Finance, US Investor Relations & Strategy
Tél. : +1 212-271-0861
susanna.mesa@dbv-technologies.com
DBV Technologies Media Contacts US & Europe
Marion Janic
Rooney & Associates
Tél. : +1-212-223-4017
mjanic@rooneyco.com
Caroline Carmagnol
Alize RP - Relation Presse
Tél. : +33(0)6 64 18 99 59
caroline@alizerp.com

PDF Version http://hugin.info/156437/R/1967515/718819.pdf

HUG#1967515

Source:DBV Technologies